Madrigal Pharmaceuticals revenue and financials
In the fiscal year ended December 2025, Madrigal Pharmaceuticals reported revenue of $958.4M (+432.05% year over year). The net loss was $288.28M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
How Madrigal Pharmaceuticals is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Shares outstanding up 45.2% in 5 years
Average diluted shares, 2020 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 0 of 5 fiscal years
Positive net income, fiscal years 2021–2025.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 958 | 180 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Cost of revenue | 56.1 | 6.2 | 0.0 | 0.0 | — | — | — | — | — | — |
| Gross profit | 902 | 174 | 0.0 | 0.0 | — | — | — | — | — | — |
| Selling, general and administrative | 814 | 435 | 108 | 48.1 | 37.3 | 21.9 | 22.6 | 15.3 | 7.7 | 6.6 |
| Research and development | 389 | 237 | 272 | 245 | 205 | 185 | 72.3 | 25.4 | 24.4 | 15.9 |
| Operating income | -300 | -498 | -380 | -294 | -242 | -207 | -95.0 | -40.7 | -32.1 | -25.2 |
| EBIT | -300 | -498 | -380 | -294 | -242 | -207 | -95.0 | -40.7 | -32.1 | -22.5 |
| EBITDA | -299 | -497 | -380 | -293 | -242 | -206 | -94.9 | -40.6 | -32.0 | -22.5 |
| Interest expense | 22.3 | 14.7 | 12.7 | 4.0 | 0.0 | 0.0 | — | — | — | 1.2 |
| Pre-tax income | -288 | -466 | -374 | -295 | -242 | -202 | -83.9 | -32.8 | -31.2 | -26.4 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| Net income | -288 | -466 | -374 | -295 | -242 | -202 | -83.9 | -32.8 | -31.2 | -26.4 |
| Net income to common shareholders | -288 | -466 | -374 | -295 | -242 | -202 | -83.9 | -32.8 | -31.2 | -26.4 |
| Basic EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -5.45 | -2.22 | -2.54 | -5.07 |
| Diluted EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -5.45 | -2.22 | -2.54 | -5.07 |
| Average shares (basic) | 22.4 | 21.3 | 18.7 | 17.1 | 16.5 | 15.4 | 15.4 | 14.8 | 12.2 | 5.2 |
| Average shares (diluted) | 22.4 | 21.3 | 18.7 | 17.1 | 16.5 | 15.4 | 15.4 | 14.8 | 12.2 | 5.2 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 364 | 311 | 321 | 287 | 213 | 137 | 103 | 62.2 | 14.6 | — | — | — |
| Cost of revenue | 40.0 | 26.8 | 24.4 | 18.1 | 9.1 | 4.5 | 3.4 | 2.2 | 0.6 | — | — | — |
| Gross profit | 324 | 284 | 297 | 269 | 204 | 133 | 99.9 | 60.0 | 14.0 | — | — | — |
| Selling, general and administrative | 289 | 269 | 240 | 209 | 197 | 168 | 141 | 108 | 105 | 80.8 | 46.5 | 27.6 |
| Research and development | 91.2 | 109 | 116 | 174 | 54.1 | 44.2 | 25.6 | 68.7 | 71.1 | 71.2 | 70.6 | 71.0 |
| Operating income | -56.3 | -92.7 | -59.6 | -114 | -47.2 | -79.3 | -67.0 | -116 | -163 | -152 | -117 | -98.5 |
| EBIT | -56.3 | -92.7 | -59.6 | -114 | -47.2 | -79.3 | -67.0 | -116 | -163 | -152 | -117 | -98.5 |
| EBITDA | -55.9 | -92.3 | -59.2 | -114 | -46.8 | -78.9 | -66.6 | -116 | -162 | -152 | -117 | -98.4 |
| Interest expense | 7.9 | 7.8 | 8.3 | 7.5 | 3.3 | 3.3 | 3.5 | 3.7 | 3.7 | 3.8 | 4.0 | 3.5 |
| Pre-tax income | -57.9 | -94.4 | -58.6 | -114 | -42.3 | -73.2 | -59.4 | -107 | -152 | -148 | -112 | -98.7 |
| Net income | -57.9 | -94.4 | -58.6 | -114 | -42.3 | -73.2 | -59.4 | -107 | -152 | -148 | -112 | -98.7 |
| Net income to common shareholders | -57.9 | -94.4 | -58.6 | -114 | -42.3 | -73.2 | -59.4 | -107 | -152 | -148 | -112 | -98.7 |
| Basic EPS | -2.51 | -3.25 | -2.57 | -5.08 | -1.90 | -2.61 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| Diluted EPS | -2.51 | -3.25 | -2.57 | -5.08 | -1.90 | -2.61 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| Average shares (basic) | 23.1 | 29.0 | 22.8 | 22.5 | 22.2 | 28.1 | 21.9 | 21.7 | 21.4 | 20.0 | 19.8 | 18.5 |
| Average shares (diluted) | 23.1 | 29.0 | 22.8 | 22.5 | 22.2 | 28.1 | 21.9 | 21.7 | 21.4 | 20.0 | 19.8 | 18.5 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,260 | 1,042 | 641 | 363 | 273 | 287 | 442 | 485 | 192 | 41.2 |
| Current assets | 1,246 | 1,033 | 637 | 361 | 272 | 285 | 440 | 485 | 192 | 41.2 |
| Cash and equivalents | 199 | 100 | 99.9 | 332 | 36.3 | 54.0 | 46.7 | 57.4 | 149 | 19.1 |
| Short-term investments | 785 | 826 | 534 | 27.2 | 234 | 230 | 392 | 426 | 42.9 | 21.4 |
| Receivables | 134 | 53.8 | 0.0 | — | — | — | — | — | — | — |
| Inventory | 74.8 | 34.1 | 0.0 | — | — | — | — | — | — | — |
| Net property, plant and equipment | 6.4 | 4.6 | 3.3 | 1.2 | 1.6 | 1.8 | 1.9 | 0.2 | 0.3 | 0.0 |
| Other intangible assets | 7.4 | 4.7 | — | — | — | — | — | — | — | — |
| Current liabilities | 310 | 169 | 119 | 116 | 76.8 | 46.6 | 25.1 | 8.4 | 10.1 | 4.8 |
| Accounts payable | 48.9 | 43.6 | 28.0 | 23.8 | 21.4 | 1.0 | 1.2 | 2.5 | 1.9 | 0.8 |
| Long-term debt | 340 | 118 | 115 | 69.7 | — | — | — | — | — | — |
| Total debt | 348 | 120 | 117 | 49.9 | 0.8 | 0.8 | 0.7 | — | — | — |
| Total liabilities | 657 | 288 | 235 | 165 | 77.2 | 47.0 | 25.5 | 8.4 | 10.1 | 4.8 |
| Total equity (incl. minority) | 603 | 754 | 405 | 197 | 196 | 240 | 417 | 477 | 182 | 36.4 |
| Retained earnings | -2,090 | -1,802 | -1,336 | -963 | -667 | -425 | -223 | -139 | -106 | -75.3 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1,245 | 1,227 | 1,260 | 1,362 | 1,015 | 997 | 1,042 | 1,073 | 1,100 | 1,082 | 641 | 238 |
| Current assets | 1,199 | 1,182 | 1,246 | 1,347 | 1,003 | 988 | 1,033 | 1,064 | 1,092 | 1,074 | 637 | 235 |
| Cash and equivalents | 293 | 227 | 199 | 296 | 186 | 184 | 100 | 233 | 495 | 623 | 99.9 | 62.1 |
| Short-term investments | 546 | 586 | 785 | 814 | 611 | 659 | 826 | 766 | 563 | 437 | 534 | 170 |
| Receivables | 192 | 187 | 134 | 113 | 79.2 | 61.4 | 53.8 | 30.5 | 6.9 | — | — | — |
| Inventory | 99.4 | 112 | 74.8 | 69.3 | 63.5 | 55.2 | 34.1 | 8.7 | 7.1 | 0.9 | — | — |
| Net property, plant and equipment | 17.2 | 14.2 | 6.4 | 8.3 | 7.5 | 4.0 | 4.6 | 4.8 | 3.2 | 3.3 | 3.3 | 2.5 |
| Other intangible assets | 7.2 | 7.3 | 7.4 | 7.5 | 4.5 | 4.6 | 4.7 | 4.8 | 4.9 | 5.0 | — | — |
| Current liabilities | 374 | 338 | 310 | 391 | 197 | 167 | 169 | 178 | 125 | 114 | 119 | 99.7 |
| Accounts payable | 34.5 | 60.8 | 48.9 | 44.9 | 38.0 | 42.1 | 43.6 | 46.0 | 9.0 | 21.5 | 28.0 | 16.5 |
| Long-term debt | 341 | 340 | 340 | 340 | 118 | 118 | 118 | 117 | 117 | 116 | 115 | 115 |
| Total debt | 348 | 347 | 348 | 346 | 124 | 120 | 120 | 119 | 118 | 118 | — | — |
| Total liabilities | 721 | 684 | 657 | 737 | 319 | 286 | 288 | 296 | 243 | 232 | 235 | 216 |
| Total equity (incl. minority) | 524 | 543 | 603 | 626 | 696 | 711 | 754 | 777 | 857 | 851 | 405 | 22.2 |
| Retained earnings | -2,243 | -2,185 | -2,090 | -2,032 | -1,918 | -1,875 | -1,802 | -1,743 | -1,636 | -1,484 | -1,336 | -1,224 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -190 | -456 | -324 | -225 | -184 | -158 | -41.6 | -25.5 | -22.3 | -17.6 |
| Depreciation and amortization | 1.5 | 1.1 | 0.5 | 0.5 | 0.4 | 0.5 | 0.1 | 0.1 | 0.1 | 0.0 |
| Capital expenditure | -0.5 | -1.5 | -1.5 | -0.2 | -0.2 | -0.3 | -0.2 | -0.0 | -0.1 | -0.0 |
| Investing cash flow | 32.3 | -274 | -503 | 207 | -5.1 | 160 | 30.7 | -380 | -22.0 | 22.0 |
| Financing cash flow | 256 | 735 | 595 | 313 | 171 | 5.1 | 0.2 | 314 | 174 | 14.5 |
| Debt issued | 350 | 0.0 | 65.0 | 50.0 | — | — | — | — | — | 8.5 |
| Debt repaid | -122 | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Effect of exchange rates | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Net change in cash | 98.8 | 5.1 | -232 | 295 | -17.7 | 7.3 | -10.7 | -91.2 | 129 | 18.8 |
| Free cash flow | -190 | -457 | -326 | -225 | -184 | — | — | — | — | — |
| Levered free cash flow | -115 | -297 | -192 | -116 | -94.6 | -86.7 | -20.0 | -14.5 | -11.4 | -2.2 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 23.3 | -167 | -133 | 79.9 | -47.1 | -88.9 | -104 | -67.0 | -135 | -149 | -79.9 | -84.9 |
| Depreciation and amortization | 1.0 | 0.8 | 1.9 | 1.9 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 |
| Capital expenditure | -4.3 | -3.8 | 0.4 | -0.9 | — | — | -0.2 | -0.8 | -0.1 | -0.4 | -1.0 | -0.3 |
| Investing cash flow | 34.2 | 192 | 27.6 | -207 | 47.9 | 164 | -48.0 | -202 | -122 | 98.1 | -362 | 50.2 |
| Financing cash flow | 3.1 | 2.3 | 9.0 | 237 | 1.7 | 8.6 | 19.8 | 7.5 | 134 | 574 | 480 | 19.6 |
| Debt issued | — | — | 0.0 | 350 | — | — | — | — | — | — | — | 15.0 |
| Debt repaid | — | — | 0.0 | -122 | — | — | — | — | — | — | — | — |
| Effect of exchange rates | 0.1 | 1.3 | 0.0 | — | 0.0 | 0.0 | — | — | — | — | — | — |
| Net change in cash | 60.7 | 28.4 | -96.9 | 110 | 2.5 | 83.6 | -133 | -262 | -123 | 523 | 37.9 | -15.1 |
| Free cash flow | 19.1 | -171 | -133 | 79.0 | -47.1 | -88.9 | -105 | -67.8 | -135 | -150 | -81.0 | -85.3 |
| Levered free cash flow | 38.2 | -111 | -120 | 113 | -37.8 | -70.1 | -76.0 | -35.8 | -92.1 | -93.0 | -42.2 | -50.7 |
Financial statements of similar companies
Companies in the group: same industry, similar size
